Skip to main content
Home > BioCentury on BioBusiness > Cover Story

Chronological Index of : Cover Story

 Current Issue
  • Figure: Price-to-earnings: BT vs RX

    Mid-cap hot streak Price-to-earnings: BT vs RX The average P/E for big biotechs was 26.2 at the end of 2Q15, up 5% from 24.9 in 1Q and 22% higher than the 10-year historical average of 21.5. Notably, the P/E for …

    Published on 7/13/2015
  • Figure: Results by market cap

    Mid-cap hot streak Results by market cap All market cap tiers above $200 million posted gains in 2Q. The top tier — companies valued above $5 billion — gained 3% and was led by a 22% move by Actelion Ltd. (SIX:…

    Published on 7/13/2015
  • Table: 2Q approvals

    Mid-cap hot streak 2Q approvals Selected second quarter approvals. Company Approval Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) EC approves an expanded label for Soliris eculizumab to treat transfusion-…

    Published on 7/13/2015
  • Table: Index performance

    Mid-cap hot streak Index performance Index 2Q15 1H15 NASDAQ Biotechnology 7% 22% BioCentury Europe 7% 20% BioCentury 100 6% 26% NYSE Arca Biotechnology 5% 22% BioCentury London 4% 6% NASDAQ …

    Published on 7/13/2015
  • Table: Restructuring watch

    Mid-cap hot streak Restructuring watch At least five companies reported workforce reductions in the second quarter compared to at least four in the same period last year. All cash and operating loss figures in $M.…

    Published on 7/13/2015
  • Figure: Biotech fund flows

    Tiers, some fears Biotech fund flows About $1.6 billion flowed into biotech funds last quarter, bringing total net inflows for the first half to $5.7 billion. This compares with $2.8 billion of net inflows in 1H14…

    Published on 7/13/2015
  • Figure: Raging bull

    Tiers, some fears Raging bull The biotech bull market now stands at 6.4 years, longer than any bull run since BioCentury created the BioCentury 100 index in the early 1990s. The next longest run, in 2003-08, …

    Published on 7/13/2015
  • Table: Follow-on performance

    Tiers, some fears Follow-on performance Fifty-eight biotechs raised $7.7 billion via follow-on offerings last quarter to bring the 1H15 total to $19.1 billion, surpassing the record total for a full year, $11.4 …

    Published on 7/13/2015
  • Table: IPO performance

    Tiers, some fears IPO performance Twenty-seven biotechs raised $3 billion via IPOs last quarter, bringing the total raised year to date to $5 billion. The 2Q IPO class is up a median of 10%, led by 200%-plus moves…

    Published on 7/13/2015
  • Table: IPO queue

    Tiers, some fears IPO queue Fifteen companies have announced plans to go public since the start of 2Q15, bringing the IPO queue to at least 23. Unless noted, companies are seeking to list on NASDAQ. Most recent …

    Published on 7/13/2015
  • Would you rather?

    How patient preference data make patient engagement real

    Data from patient preference surveys are being integrated into drug development to improve adherence, design target profiles and inform regulatory decisions.

    Published on 6/29/2015
  • Box: Devices first

    Would you rather? Devices first FDA's Center for Devices and Radiological Health has been in the vanguard of the agency's efforts to solicit patient preference data and use it to support approval decisions. In …

    Published on 6/29/2015
  • Box: Structuring benefits and risks

    Would you rather? Structuring benefits and risks The structured benefit-risk framework, a tool FDA uses for organizing and communicating benefit-risk assessments, may be one way to get patient preference data into …

    Published on 6/29/2015
  • Figure: $100M club

    Finance follows function $100M club The number of $100 million-plus venture equity rounds announced in a given year jumped sharply to nine in 2014, while prior years had seen at most three such deals. So far in …

    Published on 6/22/2015
  • Figure: Age of affluence

    Finance follows function Age of affluence Last year, private biotechs raised $9 billion — the most on record since BioCentury started tracking the data in 1994. So far in 2015, the industry has raked in $5.9 …

    Published on 6/22/2015
  • Finance follows function

    Why some VCs want their companies to spend freely in times of plenty

    VCs are opening their wallets for platforms and want their biotechs to do the same. The logic is spending increases valuations.

    Published on 6/22/2015
  • Figure: LDL Limbo

    LDL in context LDL Limbo With no outcomes data for the PCSK9 inhibitors Repatha evolocumab from Amgen Inc. (NASDAQ:AMGN) and Praluent alirocumab from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals …

    Published on 6/15/2015
  • Table: First on deck

    LDL in context First on deck There are at least five hypercholesterolemia and dyslipidemia programs in the clinic with potentially first-in-class mechanisms. Source: BCIQ: BioCentury Online Intelligence Company…

    Published on 6/15/2015
  • LDL in context

    What FDA PCSK9 panel says about LDL as a surrogate of CV benefit

    An FDA panel's vote for narrowed indications for PCSK9 mAbs Repatha and Praluent signal where LDL may and may not be an acceptable surrogate for CV benefit.

    Published on 6/15/2015
  • Box: Two baskets

    Overcoming origins Two baskets NCI expects to enroll the first of about 1,000 patients in NCI-MATCH in July. The study includes solid tumors or lymphomas harboring "actionable mutations" targeted by approved drugs…

    Published on 6/8/2015
  • Table: Basket trial roundup

    Overcoming origins Basket trial roundup At least six so-called basket trials studying genetically defined cancers across a broad spectrum of tissues of origin are under way, with at least two more slated to start …

    Published on 6/8/2015
  • Table: Target matching

    Overcoming origins Target matching The NCI-MATCH study will match patients to targeted therapies based on molecular abnormalities of their tumors, regardless of the tissue of origin. The study is starting with 10 …

    Published on 6/8/2015
  • Overcoming origins

    Why oncology drug development will remain tissue-dependent, for now

    Despite several trials studying targeted drugs across different tissue-defined cancers, the drug development and approval paradigm will remain tissue-bound for the foreseeable future.

    Published on 6/8/2015
  • Box: Rasi's annulment

    Innovators wanted? Rasi's annulment In November, the European Union Civil Service Tribunal annulled the 2011 appointment of Guido Rasi as executive director due to conflict of interest among members of the …

    Published on 6/1/2015
  • Innovators wanted?

    What new executive director could mean for EMA's innovative direction

    EMA's new executive director is due to be picked this summer, and the agency's predilections for regulatory innovation may ride on outcome.

    Published on 6/1/2015

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993